Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Latest Information Update: 07 Aug 2026
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
Most Recent Events
- 16 Jul 2026 Planned End Date changed from 1 Jun 2026 to 31 Dec 2028.
- 16 Jul 2026 Planned primary completion date changed from 1 Jun 2026 to 31 Dec 2028.
- 03 Oct 2023 Status changed from not yet recruiting to recruiting.